University of MInnesota
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT01733030
PROJECT SUMMARY:
PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred to as stimulus generalization has received surprisingly little empirical testing in the context of clinical anxiety in general, and PTSD more specifically. The current proposal represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant learning phenomenon across those with and without PTSD. The objective of this particular proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms associated with generalization of conditioned fear and 2) examine the pharmacologic modifiability of levels of generalization using a partial agonist at the NMDA receptor complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety cue) in animal studies.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Observational
Minneapolis, Minnesota, 55455, United States
To fullfill the objectives of this application, a generalization paradigm has been designed and psychophysiologically validated in which 6 rings presented on a computer screen gradually increase in size. For half of participants the smallest ring is the conditioned stimulus paired with electric shock (CS+) and the largest is the unpaired stimulus (CS-), and for the other half of participants this is reversed. Activity in fear-related brain structures measured via fMRI are predicted to gradually decrease as the presented stimulus gradually becomes less similar to the CS+, forming a generalization slope or gradient. One central hypothesis of the current application is that DCS (Seromycin) will dose dependently increase the steepness of generalization gradients (i.e., reduce fear generalization). This study will include 3 groups of healthy adults recieving either 1) 500 mg Seromycin, 2) 250 mg Seromycin, or placebo only prior to acquisition of fear conditioning. Twenty four hours later, participants will return to complete an fMRI during which brain responses to the danger cue and stimuli resembling the danger cue will be assessed.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A) Past history of hypersensitivity to Seromycin B) Current or past epileptic disorders C) Current depression D) Current anxiety disorders E) Current or past psychotic disorders F) Current or past renal disease G) Excessive or concurrent use of alcohol
a) Subjects who are unable to abstain from alcohol for 12 hours prior to testing and 2 days following testing will be excluded
250 mg versus 500 mg versus placebo effects on conditioned fear generalization
Other names: D-cycloserine
Time frame: 1/1/13-6/1/14
fMRI (BOLD) responses
Time frame: up to three years
Behavioral assessments of perceived danger
University of Minnesota
Other
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls.
Acronym: DCS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05144477
Behavior, Cardiac Arrest
New York, United States
View Trial DetailsNCT07423832
Combat Disorders, Mental Disorders
Amman, Aljubeiha, Jordan
View Trial DetailsNCT07550556
Behavior, Combat Disorders
Rome, RM, Italy
View Trial DetailsNCT06957210
Combat Disorders, Mental Disorders
Nowshera, KPK, Pakistan
View Trial Details